Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma
P. East, G. Kelly, D. Biswas, M. Marani, D. C. Hancock, T. Creasy, K. Sachsenmeier, C. Swanton, S. de Carne Trecesson, J. Downward
This study develops a transcriptional signature to measure RAS pathway activity in lung adenocarcinoma, showing it better predicts chemotherapy response and prognosis than KRAS mutation status.
bioRxiv · Apr 2, 2021Cancer Biology